查找临床试验

已按「免疫性血小板减少症」检索,对应国际通用词 immune thrombocytopenia

试验不在中国怎么办?

共找到 110 项正在招募的试验

数据更新于 23:04,每 5 分钟自动同步
正在招募II 期中国有中心NCT06794008

BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases

China

年龄 18 Years – 65 Years

Peking University People's Hospital

正在招募不适用NCT01793168

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

United States

年龄 不限 – 不限

Sanford Health

正在招募II 期中国有中心NCT07065968

The Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immune Thrombocytopenia (TEMPO-2)

China

年龄 18 Years – 不限

Peking University People's Hospital

正在招募I 期中国有中心NCT06941129

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases

China

年龄 18 Years – 不限

Institute of Hematology & Blood Diseases Hospital, China

正在招募不适用NCT05931718

Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia

Italy

年龄 18 Years – 不限

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

正在招募III 期NCT07059000

A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)

United States、Czechia、Germany、Italy、Romania 等 8 国

年龄 18 Years – 70 Years

Kedrion S.p.A.

正在招募IV 期NCT07133659

Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot Study

Iraq

年龄 18 Years – 不限

Al-Mustansiriyah University

正在招募II 期NCT07104565

Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

United States、Australia、France、Italy、Netherlands 等 7 国

年龄 18 Years – 不限

Incyte Corporation

正在招募II 期中国有中心NCT06168851

Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)

China

年龄 6 Years – 17 Years

Institute of Hematology & Blood Diseases Hospital, China

正在招募不适用中国有中心NCT06479291

The Efficacy and Safety of HCQ Plus TPO-RA in ANA Positive ITP

China、Hong Kong、Macau

年龄 15 Years – 99 Years

Yunfeng Cheng

正在招募早期 I 期中国有中心NCT06888960

Safety Study of CC312 in Autoimmune Disease Patients

China

年龄 18 Years – 不限

CytoCares Inc

正在招募不适用NCT07877727

Enhancing the Clinical Management of CMF Through a National Pediatric and Adult Network Based on Biological and Genetic Data

Italy

年龄 28 Days – 65 Years

Istituto Giannina Gaslini